Science Daily: Pharmacology News

SEPTEMBER 7, 2023

By adding synergistic self-adjuvanting properties to Covid-19 RNA vaccines, researchers showed they could significantly boost the immune response generated in mice.

RNA 240

RNA Vaccine Engineering Immune Response 240

Drug Discovery Today

APRIL 15, 2021

First subjects dosed with AKS-452, COVID-19 vaccine candidate in the Netherlands trial the vaccine is shelf-stable for 4 months at 25 degrees Celsius (77° Fahrenheit). 176 volunteers will participate in the clinical trial the safety and immune response read-outs expected in Q2 2021

Clinical Trials 113

Clinical Trials Vaccine Trials Immune Response 113

Drug Target Review

AUGUST 11, 2023

In a new development, a recent paper published in Biology Methods & Protocols by Oxford University Press has highlighted a promising avenue for enhancing vaccine efficacy against infectious pathogens like the COVID-19 virus. The implications of this finding are far-reaching, as it holds the potential to revolutionize vaccine design.

Vaccine 98

Vaccine Immune Response Bioinformatics Virus 98

SCIENMAG: Medicine & Health

JUNE 12, 2023

Peer-reviewed / Randomised Controlled Trial / People Study of healthy US adults found that a single dose of the VLA1553 vaccine candidate was generally safe, well tolerated and provokes an immune response.

Immune Response 66

Immune Response Vaccine Trials Disease 66

The Pharma Data

OCTOBER 26, 2020

AstraZeneca’s COVID-19 vaccine candidate, AZD1222, elicited immune responses in older coronavirus patients similar to ones generated in younger adults, lending more promise to a vaccine that’s seen as one of the leading contenders in the race to become the first approved COVID-19 vaccine. Source link.

Immune Response 52

Immune Response Vaccine Research 52

The Pharma Data

OCTOBER 22, 2020

AstraZeneca’s COVID-19 vaccine candidate, AZD1222, currently being evaluated in phase 3 global trials, delivers a strong immune response, according to a new UK study. Source link.

Immune Response 52

Immune Response Vaccine Trials Research 52

The Pharma Data

DECEMBER 4, 2021

The first peer-reviewed study in North America examining the timing between the first and second doses of COVID-19 mRNA vaccines shows that a longer dose interval leads to a stronger immune response. The study is funded by the Government of Canada through its COVID-19 Immunity Task Force (CITF).

Immune Response 52

Immune Response Vaccine Hospitals Laboratories 52

ASPET

AUGUST 3, 2023

Mechanistic modeling can be used to describe the time course of vaccine-induced humoral immunity and to identify key biological drivers in antibody production. We utilized a six-compartment mechanistic model to describe a 20-week time course of humoral immune responses in 56 non-human primates (NHPs) elicited by vaccination with Ad26.COV2.S

Vaccine 100

Vaccine Immune Response Production Drugs 100

DrugBank

MARCH 12, 2025

The COVID-19 pandemic brought mRNA to global prominence by developing highly effective vaccines by Moderna and Pfizer-BioNTech. Cancer immunotherapy , which harnesses the body’s immune system to identify and destroy malignant cells, has traditionally relied on biologics such as immune checkpoint inhibitors.

Vaccine 97

Vaccine Treatment Clinical Trials Therapies 97

The Pharma Data

SEPTEMBER 10, 2020

Pfizer-BioNTech announced Wednesday that preliminary preclinical data from mouse and macaque monkey models showed a strong immune response from its mRNA COVID-19 vaccine. . Tareq Aziz Touhid. The study and the data are currently subject to peer review.

Immune Response 52

Immune Response Vaccine RNA Research 52

The Pharma Data

AUGUST 16, 2021

The study assessed cynomolgus macaques vaccinated with 12µg of either the first or second-generation vaccine candidate. During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages.

Immune Response 52

Immune Response Vaccine Virus RNA 52

The Pharma Data

AUGUST 27, 2020

Moderna has announced that its coronavirus vaccine candidate has shown promise in generating an immune response in elderly patients in an early-stage clinical trial. . Each patient was given two 100 microgram doses of the vaccine 28 days apart. There is hope that Moderna’s vaccine could be available by early 2021. .

Vaccine 90

Vaccine Immune Response Clinical Trials Virus 90

The Pharma Data

MAY 16, 2021

Adjuvanted recombinant COVID-19 vaccine candidate triggered strong neutralizing antibody responses in all adult age groups. High immune response after a single dose in patients with prior infection shows strong booster potential. Global Phase 3 study expected to start in the coming weeks. 1.351 (South African) variants.

Immune Response 52

Immune Response Vaccine Trials Treatment 52

The Pharma Data

NOVEMBER 10, 2020

Canadian biopharmaceutical company Medicago has announced that its investigational COVID-19 vaccine generated “significant antibody and cellular immune responses” after two doses in all subjects in an early-stage clinical trial. microgram or 15-microgram doses of the vaccine candidate, either alone or with an adjuvant.

Immune Response 40

Immune Response Vaccine Clinical Trials Virus 40

SCIENMAG: Medicine & Health

JULY 24, 2023

A new paper in Biology Methods & Protocols, published by Oxford University Press, shows it may be possible to design vaccines that will induce a stronger immune response to infecting pathogens, such as the virus causing COVID-19.

Vaccine 60

Vaccine Bioinformatics Immune Response Virus 60

The Pharma Data

OCTOBER 25, 2020

German drugmaker CureVac said preclinical studies of its COVID-19 vaccine candidate, CVnCoV, showed the vaccination prompted a successful immune response. The vaccine is currently being evaluated in phase 1 and 2 human clinical trials. Source link.

Vaccine 52

Vaccine Immune Response RNA Clinical Trials 52

The Pharma Data

SEPTEMBER 4, 2020

The findings have validated confidence in the experimental vaccine, the firm noted. Janssen’s lead SARS-CoV-2 investigational vaccine candidate, Ad26.COV2.S, S, prevented severe clinical disease in Syrian golden hamsters when challenged with SARS-CoV-2, the virus that causes COVID-19 in people.

Vaccine 52

Vaccine Immune Response Disease Virus 52

The Pharma Data

NOVEMBER 2, 2020

German biopharma company CureVac announced yesterday that its COVID-19 vaccine hopeful generated immune responses and was generally well-tolerated in phase 1 trial participants, lending support for a pivotal trial before year’s end. Source link.

Vaccine 52

Vaccine Trials Immune Response Research 52

The Pharma Data

DECEMBER 12, 2020

Sanofi and GlaxoSmithKline (GSK) have decided to push back the phase 2b trial of their adjuvanted COVID-19 vaccine after finding it produced only a weak immune response in older patients, delaying the potential delivery of a vaccine that could contribute to the mass vaccination effort in the U.S. James Miessler.

Vaccine 52

Vaccine Immune Response Trials Research 52

The Pharma Data

APRIL 15, 2022

NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced positive results from a Phase 2/3 clinical trial evaluating the safety, tolerability and immunogenicity of a 10-µg booster (third) dose of the Pfizer-BioNTech COVID-19 vaccine in healthy children 5 through 11 years of age. About Pfizer: Breakthroughs That Change Patients’ Lives.

Immune Response 52

Immune Response Vaccine Clinical Trials Virus 52

The Pharma Data

SEPTEMBER 25, 2020

A trial of a new vaccine that appears to train the immune system to fight coronavirus has begun in the UK. The trial on 10,000 people will now see if the vaccine can prevent people getting ill. A vaccine that can protect people from Covid-19 is still widely seen as the main exit strategy from the restrictions on all our lives.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

DECEMBER 8, 2020

8, 2020 — AstraZeneca’s COVID-19 vaccine is safe and effective, new data from late-stage trials shows. Overall, the vaccine protected against symptomatic disease in 70% of cases, according to a team led by researchers from Oxford University in England. TUESDAY, Dec. 8 in The Lancet.

Vaccine 52

Vaccine Trials Immune Response RNA 52

The Pharma Data

DECEMBER 20, 2020

UK drug developer Scancell said it has chosen a COVID-19 vaccine candidate, SN14, from more than a dozen potential products to advance to a clinical trial. . SN14 works by targeting the coronavirus’ nucleocapsid and spike proteins to prevent viral replication using the company’s ImmunoBody DNA vaccine technology. Source link.

Clinical Trials 52

Clinical Trials Vaccine Pharma Companies Trials 52

The Pharma Data

DECEMBER 11, 2020

The Australian government has scrapped a supply deal with CSL for 51 million doses of its COVID-19 vaccine co-developed with the University of Queensland, after trial participants falsely tested positive for HIV.

Vaccine 52

Vaccine Immune Response Trials Government 52

The Pharma Data

JANUARY 9, 2021

9, 2021 — A task force of allergists and immunologists recommends those administering the COVID-19 vaccine ask patients some key questions beforehand. If the answer is yes, the individual should be referred to a board-certified allergist for evaluation before getting the COVID-19 vaccination, ACAAI said in a news release.

Vaccine 52

Vaccine Immune Response Doctors Disease 52

The Pharma Data

SEPTEMBER 25, 2020

Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate. Johnson & Johnson Posts Interim Results from Phase 1/2a Clinical Trial of its Janssen COVID-19 Vaccine Candidate. Immune responses were similar across the age groups studied, including older adults.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

SEPTEMBER 14, 2020

. AstraZeneca has confirmed that clinical trials assessing its Oxford University partnered coronavirus vaccine AZD1222 have resumed in the UK, following a green light by the Medicines Health Regulatory Authority (MHRA). Source link.

Vaccine 52

Vaccine Trials Immune Response Virus 52

The Pharma Data

FEBRUARY 22, 2021

Sanofi and GSK initiate new Phase 2 study of their adjuvanted recombinant protein-based COVID-19 vaccine candidate. New Phase 2 study assesses potential for refined antigen formulation to achieve optimal immune response, including in older adults. In parallel, development work on new SARS-CoV-2 variants underway.

Vaccine 52

Vaccine Immune Response Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 30, 2021

Anderson Professor of Chemical and Biomolecular Engineering, and his colleagues, are reporting in iScience the event of an intranasal subunit vaccine that gives durable local immunity against inhaled pathogens. A fundamental limitation of intramuscular vaccines is that they’re not designed to elicit mucosal immunity.

Vaccine 52

Vaccine Disease Immune Response Virus 52

The Pharma Data

AUGUST 7, 2020

New Phase 1/2 on Novavax’s COVID-19 vaccine candidate NVX?CoV2373 CoV2373 has shown that the therapy generated “robust antibody responses” when used with or without the company’s Matrix?M tolerated COVID-19 vaccine with a robust immunogenicity profile,” explained Dr Gregory Glenn, President of Research and Development at Novavax.

Vaccine 52

Vaccine Immune Response Virus Therapies 52

The Pharma Data

DECEMBER 7, 2020

China’s Clover Biopharmaceuticals has announced its COVID-19 S Trimer vaccine candidate delivered a “strong immune response” in 150 adult and elderly phase 1 trial participants, with pre-publication results to be released soon.

Vaccine 52

Vaccine Immune Response Trials Research 52

The Pharma Data

SEPTEMBER 2, 2020

. Sanofi and GSK have begun a Phase I/II clinical trial testing their adjuvanted COVID-19 vaccine in healthy adults. The vaccine candidate, developed in partnership by the firms, is based on the recombinant protein-based technology used in Sanofi’s seasonal influenza vaccines and GSK’s pandemic adjuvant technology.

Vaccine 52

Vaccine Trials Immune Response Clinical Trials 52

The Pharma Data

DECEMBER 3, 2020

The Phase 1 trial was a randomized, observer-blind, placebo-controlled study to assess the safety, reactogenicity and immunogenicity of the adjuvanted COVID-19 S-Trimer vaccine candidates formulated with different antigen levels. No serious adverse events related to the vaccine candidates studied were reported.

Vaccine 52

Vaccine Immune Response Virus RNA 52

The Pharma Data

DECEMBER 22, 2020

22, 2020 — In very rare cases, some people have had severe allergic reactions after receiving the new COVID-19 vaccines, leading the American College of Allergy , Asthma, and Immunology (ACAAI) to issue updated guidance for Americans with allergies. TUESDAY, Dec. per 1 million doses given to patients, according to the ACAAI.

Vaccine 52

Vaccine Immune Response Treatment Disease 52

The Pharma Data

DECEMBER 14, 2020

Supported by promising phase 1 data, CureVac announced Monday that it has enrolled the first participant in the pivotal phase 2b/3 study of its messenger-RNA based coronavirus vaccine, CVnCoV. The company announced positive phase 1 trial results in November that demonstrated its candidate elicited immune responses and was well-tolerated.

Vaccine 52

Vaccine Trials Immune Response RNA 52

The Pharma Data

JUNE 24, 2021

The primary objective in the trial is to describe safety when both vaccines are co-administered, with follow up six months after vaccination. Secondary objectives are to describe immune responses produced by each of the vaccines. Pfizer-BioNTech COVID-19 Vaccine booster plus placebo. 20vPnC plus placebo.

Vaccine 52

Vaccine Immune Response FDA Licensing 52

The Pharma Data

JANUARY 25, 2021

25, 2021 — Giving melanoma patients a “personalized” vaccine can prompt an anti-tumor immune response that lasts for years, an early study finds. But it builds on earlier work showing it is possible to spur the immune system to respond to an individual’s unique tumor. MONDAY, Jan.

Vaccine 52

Vaccine Immune Response Medical Schools Clinical Trials 52